Building a computational model of E.coli

Our whole cell computational model of E.coli is being utilised to reveal new biology, identify viable first-in-class targets and build a pipeline of novel antibacterial drugs.

Our modelling approach is different from others in that we go into much higher level of detail allowing us to identify non-intuitive drug targets

  • Antimicrobial compounds

  • Bacteria

  • Human
  • Veterinary

Development stage:
  • Research
  • Development

  • Company

  • License, Co-develop, Outsource, Joint Venture

Pharma/Biotechs/Academic institutes

Oppilotech develops first-in-class antibacterial drugs – the drug targets are identified using a platform based on systems biology and ML

Oppilotech have built up a bacterial isolate collection and also undertake microbiology services (MIC, MBC testing, Time/Kill Post Antibiotic Effect Analysis & Serial Passage/Mutation Frequency Testing) for clients developing antibacterial products

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!